G1 THERAPEUTICS

g1-therapeutics-logo

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.

#SimilarOrganizations #People #Financial #Event #Website #More

G1 THERAPEUTICS

Social Links:

Industry:
Biotechnology Developer Platform Medical Therapeutics

Founded:
2008-01-01

Address:
Durham, North Carolina, United States

Country:
United States

Website Url:
http://www.g1therapeutics.com

Total Employee:
101+

Status:
Active

Contact:
+1 919 213 9835

Email Addresses:
[email protected]

Total Funding:
497.32 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Amazon


Similar Organizations

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

proteostasis-therapeutics-logo

Proteostasis Therapeutics

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.

scholar-rock-logo

Scholar Rock

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.


Current Advisors List

seth-rudnick_image

Seth Rudnick Chairman @ G1 Therapeutics
Board_member
2014-01-07

christy-l-shaffer_image

Christy L. Shaffer Executive Chair, Board @ G1 Therapeutics
Board_member

jack-bailey_image

Jack Bailey Board Member @ G1 Therapeutics
Board_member
2020-03-01

Current Employees Featured

rajesh-malik_image

Rajesh Malik
Rajesh Malik Chief Medical Officer @ G1 Therapeutics
Chief Medical Officer
2014-01-01

not_available_image

Jay Strum
Jay Strum Chief Scientific Officer @ G1 Therapeutics
Chief Scientific Officer

terry-murdock_image

Terry Murdock
Terry Murdock Chief Operating Officer @ G1 Therapeutics
Chief Operating Officer
2017-08-01

greg-mossinghoff_image

Greg Mossinghoff
Greg Mossinghoff Chief Business Officer @ G1 Therapeutics
Chief Business Officer

jennifer-moses_image

Jennifer Moses
Jennifer Moses Chief Financial Officer & VP of Finance @ G1 Therapeutics
Chief Financial Officer & VP of Finance
2019-05-01

ostra-jewell_image

Ostra Jewell
Ostra Jewell Vice President Human Resources @ G1 Therapeutics
Vice President Human Resources
2019-08-01

mark-avagliano_image

Mark Avagliano
Mark Avagliano Chief Business Officer @ G1 Therapeutics
Chief Business Officer
2019-01-01

andrew-perry_image

Andrew Perry
Andrew Perry Chief Commercial Officer @ G1 Therapeutics
Chief Commercial Officer
2021-08-01

greg-maxfield_image

Greg Maxfield
Greg Maxfield VP & Market Access @ G1 Therapeutics
VP & Market Access
2020-06-01

jack-bailey_image

Jack Bailey
Jack Bailey CEO @ G1 Therapeutics
CEO
2021-01-01

Founder


kwok-kin-wong_image

Kwok-Kin Wong

norman-sharpless_image

Norman Sharpless

Stock Details


Company's stock symbol is NASDAQ:GTHX

Investors List

herculescapital_image

Hercules Capital

Hercules Capital investment in Post-IPO Debt - G1 Therapeutics

tavistock-life-sciences_image

Tavistock Life Sciences

Tavistock Life Sciences investment in Series C - G1 Therapeutics

franklin-templeton-investments_image

Franklin Templeton Investments

Franklin Templeton Investments investment in Series C - G1 Therapeutics

cowen-group_image

Cowen Group

Cowen Group investment in Series C - G1 Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - G1 Therapeutics

eshelman-ventures_image

Eshelman Ventures

Eshelman Ventures investment in Series C - G1 Therapeutics

aju-ib-investment_image

Aju IB Investment

Aju IB Investment investment in Series C - G1 Therapeutics

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series C - G1 Therapeutics

mountain-group-capital_image

Mountain Group Capital

Mountain Group Capital investment in Series C - G1 Therapeutics

lumira-ventures_image

Lumira Ventures

Lumira Ventures investment in Series C - G1 Therapeutics

Official Site Inspections

http://www.g1therapeutics.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.34 K

  • Host name: ec2-18-233-60-122.compute-1.amazonaws.com
  • IP address: 18.233.60.122
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "G1 Therapeutics"

G1 Therapeutics - Crunchbase Company Profile

Contact Email [email protected] Phone Number +1 919 213 9835 G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.See details»

G1 Therapeutics - Wikipedia

G1 Therapeutics was co-founded in 2008 by Norman Sharpless, 15th Director of the National Cancer Institute, and Kwok-Kin Wong, to develop and commercialize drug candidates discovered at, and licensed from, Sharplessโ€™ lab at the University of North Carolina at Chapel Hill. Early investors in G1 included Hatteras Venture Partners, and Fred Eshelman, founder of PPD, Inc. Other early investors included AstraZenecaโ€™s venture capital fund MedImmune Ventures, and Coโ€ฆSee details»

G1 Therapeutics, Inc. | Optimizing Chemotherapy, Advancing Survival

G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer.See details»

G1 Therapeutics - Overview, News & Similar companies - ZoomInfo

May 23, 2024 G1 Therapeutics contact info: Phone number: (919) 213-9835 Website: www.g1therapeutics.com What does G1 Therapeutics do? Founded in 2008, G1 Therapeutics โ€ฆSee details»

G1 Therapeutics, Inc. Company Profile - Dun & Bradstreet

Company Description: G1 Therapeutics is a biopharmaceutical firm working to develop and delivery of next generation therapies that improve the lives of people affected by cancer. The โ€ฆSee details»

G1 Therapeutics Company Profile | Management and Employees โ€ฆ

SQL International Organization for Standardization . Python Python . Java Oracle . Other Communication and Collaboration Software (4 Technologies) Microsoft Excel Microsoft . ...See details»

G1 Therapeutics, Inc. | LinkedIn

G1 Therapeutics, Inc. | 16,540 followers on LinkedIn. Our mission is to discover, develop and deliver next generation cancer therapies. | G1 Therapeutics, Inc. is a wholly owned subsidiary โ€ฆSee details»

G1 Therapeutics, Inc. Company Overview, Contact Details

Nov 17, 2022 [email protected]: [email protected]: 1%. [email protected]: [email protected]: 1%. See more formats. โ€ฆSee details»

G1 Therapeutics - PitchBook

G1 Therapeutics General Information Description. G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to โ€ฆSee details»

G1 Therapeutics - Craft

Jul 19, 2024 G1 Therapeutics has 5 employees at their 1 location and $82.51 m in annual revenue in FY 2023. See insights on G1 Therapeutics including office locations, competitors, โ€ฆSee details»

G1 Therapeutics, Inc. Information - RocketReach

What is the annual revenue of G1 Therapeutics, Inc.? The G1 Therapeutics, Inc. annual revenue was $24.2 million in 2024.See details»

G1 Therapeutics - Golden

G1 Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina that was founded in 2008 by Kwok-Kin Wong and โ€ฆSee details»

G1 Therapeutics Announces Appointment of Andrew Perry as โ€ฆ

Aug 2, 2021 Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 โ€ฆSee details»

Pharmacosmos Group and G1 Therapeutics Announce Successful โ€ฆ

Following the closing of the tender offer, on September 18, 2024 Purchaser merged with and into G1 Therapeutics, with G1 Therapeutics continuing as the surviving corporation and a wholly โ€ฆSee details»

Working At G1 Therapeutics: Company Overview and Culture

Www.g1therapeutics.com. Organization Type. Public. Social Media. G1 Therapeutics is a clinical stage company developing novel cancer therapies. G1T was founded in 2008 by Drs. Norman โ€ฆSee details»

G1 Therapeutics - VentureRadar

Auto Analyst Score: 56 | g1therapeutics.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times โ€ฆSee details»

G1 Therapeutics Provides Third Quarter 2021 Financial Results and ...

Nov 3, 2021 The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. A live and archived webcast โ€ฆSee details»

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in โ€ฆ

Jun 24, 2024 โ€œThe unexpected results from PRESERVE 2 underscore the challenge of developing new therapies for triple negative breast cancer,โ€ said Jack Bailey, Chief Executive โ€ฆSee details»

G1 Therapeutics Provides First Quarter 2020 Corporate and โ€ฆ

Mar 31, 2020 The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 5669692. A live and archived webcast โ€ฆSee details»

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in โ€ฆ

Jun 24, 2024 While not required, it is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the โ€ฆSee details»

linkstock.net © 2022. All rights reserved